OKAY
833230
CHANGFU CO.,LTD
871396
Gansu Longshenrongfa Pharmaceutical Industry
300534
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -31.46%386.27M | -33.70%83.69M | -34.77%95.19M | -29.87%100.72M | -27.84%106.67M | 12.28%563.61M | -17.20%126.22M | -8.54%145.94M | 30.99%143.63M | 84.00%147.82M |
Operating revenue | -31.46%386.27M | -33.70%83.69M | -34.77%95.19M | -29.87%100.72M | -27.84%106.67M | 12.28%563.61M | -17.20%126.22M | -8.54%145.94M | 30.99%143.63M | 84.00%147.82M |
Cost of revenue | -16.86%208.09M | -27.08%46.66M | -15.55%49.98M | -12.10%53.85M | -12.53%57.6M | -1.79%250.28M | -6.65%63.98M | -22.93%59.18M | 7.29%61.26M | 25.63%65.86M |
Gross profit | -43.13%178.18M | -40.50%37.03M | -47.89%45.21M | -43.10%46.87M | -40.13%49.07M | 26.79%313.32M | -25.82%62.24M | 4.81%86.76M | 56.75%82.37M | 193.61%81.96M |
Operating expense | -4.57%69.4M | 1.03%16.23M | -9.56%17.22M | -1.65%17.32M | -6.88%18.63M | -0.06%72.72M | -18.40%16.06M | -16.60%19.04M | 19.69%17.61M | 28.78%20.01M |
Selling and administrative expenses | -3.33%54.26M | 3.52%12.63M | -12.79%13.32M | 0.00%13.46M | -2.26%14.86M | -3.05%56.13M | -23.19%12.2M | -20.26%15.27M | 21.20%13.46M | 29.25%15.2M |
Depreciation amortization depletion | 1.90%15.64M | 2.02%3.95M | 1.67%3.9M | 1.74%3.91M | 2.16%3.89M | 3.50%15.35M | 4.68%3.87M | 7.93%3.84M | 7.14%3.84M | -4.81%3.8M |
-Depreciation and amortization | 1.90%15.64M | 2.02%3.95M | 1.67%3.9M | 1.74%3.91M | 2.16%3.89M | 3.50%15.35M | 4.68%3.87M | 7.93%3.84M | 7.14%3.84M | -4.81%3.8M |
Other operating expenses | -140.45%-502K | -11,366.67%-344K | 97.18%-2K | -114.79%-46K | -110.96%-110K | 3,347.22%1.24M | -102.73%-3K | -158.68%-71K | 1,195.83%311K | 558.45%1M |
Operating profit | -54.79%108.78M | -54.95%20.8M | -58.66%27.99M | -54.37%29.55M | -50.87%30.44M | 37.99%240.61M | -28.09%46.18M | 12.97%67.72M | 71.17%64.76M | 400.42%61.96M |
Net non-operating interest income expense | 26.59%-16.62M | 19.68%-3.95M | 23.02%-3.81M | 19.01%-4.27M | 38.82%-4.59M | 37.67%-22.64M | 40.06%-4.91M | 44.27%-4.95M | 45.42%-5.28M | 21.67%-7.5M |
Non-operating interest income | 61.83%6.7M | 62.93%1.92M | 100.40%2.03M | 137.12%1.55M | -6.94%1.21M | 167.72%4.14M | -15.54%1.18M | 574.00%1.01M | --652K | --1.3M |
Non-operating interest expense | -7.02%22.22M | -1.17%5.59M | 5.42%5.56M | 5.36%5.55M | -28.28%5.53M | -28.16%23.9M | -33.28%5.65M | -32.81%5.28M | -38.10%5.27M | -8.68%7.7M |
Total other finance cost | -61.89%1.1M | -36.14%281K | -59.74%277K | -58.97%272K | -75.41%268K | -37.44%2.88M | -60.78%440K | -41.99%688K | -42.89%663K | -4.05%1.09M |
Other net income (expense) | -90.05%675K | 0 | -57.36%675K | 121.37%6.78M | 162.51%7.1M | 87.12%-2.58M | -20.87%675K | 229.01%1.58M | ||
Gain on sale of security | -92.55%675K | --0 | ---- | ---- | -81.81%675K | 128.56%9.06M | 163.84%7.25M | 87.12%-2.58M | -20.87%675K | 402.44%3.71M |
Special income (charges) | --0 | --0 | --0 | --0 | --0 | ---2.28M | ---151K | --0 | --0 | ---2.13M |
-Less:Other special charges | ---- | ---- | ---- | ---- | ---- | --2.28M | --151K | ---- | ---- | --2.13M |
Income before tax | -58.69%92.84M | -65.15%16.86M | -59.83%24.18M | -57.98%25.28M | -52.67%26.53M | 111.41%224.75M | 8.31%48.37M | 93.82%60.19M | 107.30%60.16M | 3,442.48%56.04M |
Income tax | -58.02%21.43M | -59.02%4.31M | -72.04%4.08M | -49.70%6.89M | -49.72%6.14M | 57.71%51.05M | -19.58%10.52M | 21.42%14.61M | 122.16%13.7M | 1,022.89%12.22M |
Net income | -58.89%71.41M | -66.85%12.54M | -55.91%20.09M | -60.42%18.39M | -53.49%20.38M | 134.92%173.7M | 19.86%37.84M | 139.61%45.58M | 103.29%46.45M | 8,771.46%43.83M |
Net income continuous Operations | -58.89%71.41M | -66.85%12.54M | -55.91%20.09M | -60.42%18.39M | -53.49%20.38M | 134.92%173.7M | 19.86%37.84M | 139.61%45.58M | 103.29%46.45M | 8,771.46%43.83M |
Minority interest income | 142K | 42K | 100K | 0 | 0 | 0 | ||||
Net income attributable to the parent company | -58.97%71.27M | -66.96%12.5M | -56.13%19.99M | -60.42%18.39M | -53.49%20.38M | 134.92%173.7M | 19.86%37.84M | 139.61%45.58M | 103.29%46.45M | 8,771.46%43.83M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -58.97%71.27M | -66.96%12.5M | -56.13%19.99M | -60.42%18.39M | -53.49%20.38M | 134.92%173.7M | 19.86%37.84M | 139.61%45.58M | 103.29%46.45M | 8,771.46%43.83M |
Basic earnings per share | -58.48%0.71 | -64.86%0.13 | -55.56%0.2 | -60.87%0.18 | -54.55%0.2 | 125.00%1.71 | 15.63%0.37 | 125.00%0.45 | 91.67%0.46 | 4,300.00%0.44 |
Diluted earnings per share | -55.13%0.7 | -58.62%0.12 | -53.49%0.2 | -59.09%0.18 | -47.37%0.2 | 110.81%1.56 | -6.45%0.29 | 115.00%0.43 | 83.33%0.44 | 3,700.00%0.38 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |